Showing results (281-290 of 319) with videos related to

Sort By:
Pageof 32
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 28, 2021
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survivalFilippo Pelizzaro, Giulia Peserico, Marco D'Elia, et al.
Liver Cancer|May 12, 2021
Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationClaudia Campani, Alessandro Vitale, Gabriele Dragoni, et al.
Scientific Reports|November 23, 2025
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus BevacizumabAndrea Dalbeni, Filippo Cattazzo, Marco Vicardi, et al.
JHEP Reports : Innovation in Hepatology|August 4, 2023
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver diseaseGrazia Pennisi, Marco Enea, Mauro Viganò, et al.
Gut|December 22, 2021
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA databaseAlessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, et al.
Hepatology (Baltimore, Md.)|August 3, 2022
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction modelFrancesco Vizzutti, Ciro Celsa, Vincenza Calvaruso, et al.
JHEP Reports : Innovation in Hepatology|June 11, 2026
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinomaAnne Victoire Odent, Claudia Campani, Mohamed Bouattour, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 23, 2020
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter studyGiovanni Marasco, Antonio Colecchia, Maria Letizia Bacchi Reggiani, et al.
Hepatology Communications|July 28, 2025
Outcome of hepatic resection for HCC in ideal and non-ideal candidatesLorenzo Lani, Laura Bucci, Valentina Santi, et al.
Pageof 32